$MIRM
Mirum Pharmaceuticals, Inc.

2021 Q1 Form 10-K Financial Statement

#000156459021011756 Filed on March 09, 2021

View on sec.gov

Income Statement

Concept 2021 Q1 2019 Q4 2019
Revenue $0.00 $0.00 $0.00
YoY Change
Cost Of Revenue
YoY Change
Gross Profit
YoY Change
Gross Profit Margin
Selling, General & Admin $9.479M $4.280M $11.75M
YoY Change 102.11% 1891.53%
% of Gross Profit
Research & Development $38.13M $14.38M $42.99M
YoY Change 119.92% 1745.11%
% of Gross Profit
Depreciation & Amortization $90.00K $60.00K $139.0K
YoY Change 23.29%
% of Gross Profit
Operating Expenses $47.61M $18.66M $54.74M
YoY Change 116.11% 1774.76%
Operating Profit -$47.61M -$54.74M
YoY Change 116.11%
Interest Expense -$2.900M $730.0K $2.210M
YoY Change -486.67% 3583.33%
% of Operating Profit
Other Income/Expense, Net -$16.00K -$21.00K
YoY Change -30.43%
Pretax Income -$50.53M -$17.93M -$52.53M
YoY Change 137.15% 202.78%
Income Tax $5.000K $20.00K $21.00K
% Of Pretax Income
Net Earnings -$50.53M -$17.95M -$52.55M
YoY Change 137.13% 202.9%
Net Earnings / Revenue
Basic Earnings Per Share
Diluted Earnings Per Share -$1.678M -$779.8K -$2.283M
COMMON SHARES
Basic Shares Outstanding 30.42M 22.99M
Diluted Shares Outstanding

Balance Sheet

Concept 2021 Q1 2019 Q4 2019
SHORT-TERM ASSETS
Cash & Short-Term Investments $213.1M $116.7M $116.7M
YoY Change 33.59% 124.42%
Cash & Equivalents $90.68M $11.97M $12.00M
Short-Term Investments $122.4M $104.7M $104.7M
Other Short-Term Assets $4.600M $2.700M $2.700M
YoY Change 58.62%
Inventory
Prepaid Expenses
Receivables
Other Receivables
Total Short-Term Assets $217.8M $119.4M $119.4M
YoY Change 34.11% 129.65% 129.62%
LONG-TERM ASSETS
Property, Plant & Equipment $3.100M $1.372M $3.700M
YoY Change 121.9%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments $23.30M $23.30M
YoY Change
Other Assets $1.426M $324.0K $300.0K
YoY Change 791.25%
Total Long-Term Assets $4.441M $27.35M $27.30M
YoY Change -57.31%
TOTAL ASSETS
Total Short-Term Assets $217.8M $119.4M $119.4M
Total Long-Term Assets $4.441M $27.35M $27.30M
Total Assets $222.2M $146.7M $146.7M
YoY Change 28.61% 182.27% 182.12%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable $5.658M $3.351M $3.400M
YoY Change 73.29% 1145.72% 1033.33%
Accrued Expenses $27.78M $9.328M $9.700M
YoY Change 184.29% 327.89% 340.91%
Deferred Revenue
YoY Change
Short-Term Debt $0.00 $0.00 $0.00
YoY Change
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities $35.00M $13.08M $13.10M
YoY Change 158.34% 433.93% 445.83%
LONG-TERM LIABILITIES
Long-Term Debt $0.00 $0.00 $0.00
YoY Change
Other Long-Term Liabilities $24.00K $36.00K $3.300M
YoY Change -29.41%
Total Long-Term Liabilities $24.00K $36.00K $3.300M
YoY Change -29.41%
TOTAL LIABILITIES
Total Short-Term Liabilities $35.00M $13.08M $13.10M
Total Long-Term Liabilities $24.00K $36.00K $3.300M
Total Liabilities $88.36M $16.36M $16.40M
YoY Change 429.57% 568.15% 583.33%
SHAREHOLDERS EQUITY
Retained Earnings -$223.7M -$69.90M
YoY Change 145.26% 302.93%
Common Stock $357.6M $200.1M
YoY Change 44.57% 571674.29%
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity $133.9M $130.3M $130.3M
YoY Change
Total Liabilities & Shareholders Equity $222.2M $146.7M $146.7M
YoY Change 28.61% 182.27% 182.12%

Cashflow Statement

Concept 2021 Q1 2019 Q4 2019
OPERATING ACTIVITIES
Net Income -$50.53M -$17.95M -$52.55M
YoY Change 137.13% 202.9%
Depreciation, Depletion And Amortization $90.00K $60.00K $139.0K
YoY Change 23.29%
Cash From Operating Activities -$25.21M -$13.70M -$39.36M
YoY Change 37.38% 10538.38%
INVESTING ACTIVITIES
Capital Expenditures $3.000K -$70.00K $281.0K
YoY Change -96.94% -103.75%
Acquisitions
YoY Change
Other Investing Activities -$32.78M -$5.080M -$127.5M
YoY Change -196.81%
Cash From Investing Activities -$32.78M -$5.140M -$127.8M
YoY Change -197.11% 1603.75%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net $0.00
YoY Change -100.0%
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities 6.594M 0.000 127.2M
YoY Change -85.23% 112.53%
NET CHANGE
Cash From Operating Activities -25.21M -13.70M -39.36M
Cash From Investing Activities -32.78M -5.140M -127.8M
Cash From Financing Activities 6.594M 0.000 127.2M
Net Change In Cash -51.41M -18.84M -39.99M
YoY Change -185.59% -176.95%
FREE CASH FLOW
Cash From Operating Activities -$25.21M -$13.70M -$39.36M
Capital Expenditures $3.000K -$70.00K $281.0K
Free Cash Flow -$25.21M -$13.63M -$39.64M
YoY Change 36.66% -656.0%

Facts In Submission

Frame Concept Type Concept / XBRL Key Value Unit
CY2020 dei Document Period End Date
DocumentPeriodEndDate
2020-12-31
CY2020 dei Document Fiscal Period Focus
DocumentFiscalPeriodFocus
FY
CY2020 dei Current Fiscal Year End Date
CurrentFiscalYearEndDate
--12-31
CY2020 dei Amendment Flag
AmendmentFlag
false
CY2020 dei Document Type
DocumentType
10-K
CY2020 dei Document Fiscal Year Focus
DocumentFiscalYearFocus
2020
CY2020 dei Entity Registrant Name
EntityRegistrantName
Mirum Pharmaceuticals, Inc.
CY2020 dei Entity Central Index Key
EntityCentralIndexKey
0001759425
CY2020 dei Entity Current Reporting Status
EntityCurrentReportingStatus
Yes
CY2020 dei Entity Filer Category
EntityFilerCategory
Non-accelerated Filer
CY2020 dei Entity Interactive Data Current
EntityInteractiveDataCurrent
Yes
CY2020 dei Entity Voluntary Filers
EntityVoluntaryFilers
No
CY2020 dei Entity Well Known Seasoned Issuer
EntityWellKnownSeasonedIssuer
No
CY2020Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
142086000
CY2020 dei Entity Small Business
EntitySmallBusiness
true
CY2020 dei Entity Emerging Growth Company
EntityEmergingGrowthCompany
true
CY2020 dei Entity Ex Transition Period
EntityExTransitionPeriod
true
CY2020 dei Entity File Number
EntityFileNumber
001-38981
CY2020 dei Icfr Auditor Attestation Flag
IcfrAuditorAttestationFlag
false
CY2020Q2 dei Entity Public Float
EntityPublicFloat
243500000
CY2021Q1 dei Entity Common Stock Shares Outstanding
EntityCommonStockSharesOutstanding
30419707
CY2020 dei Entity Shell Company
EntityShellCompany
false
CY2020 dei Entity Incorporation State Country Code
EntityIncorporationStateCountryCode
DE
CY2020 dei Entity Tax Identification Number
EntityTaxIdentificationNumber
83-1281555
CY2020 dei Entity Address Address Line1
EntityAddressAddressLine1
950 Tower Lane, Suite 1050,
CY2020 dei Entity Address City Or Town
EntityAddressCityOrTown
Foster City
CY2020 dei Entity Address State Or Province
EntityAddressStateOrProvince
CA
CY2020 dei Entity Address Postal Zip Code
EntityAddressPostalZipCode
94404
CY2020 dei City Area Code
CityAreaCode
650
CY2020 dei Local Phone Number
LocalPhoneNumber
667-4085
CY2020 dei Document Transition Report
DocumentTransitionReport
false
CY2020 dei Document Annual Report
DocumentAnnualReport
true
CY2020 dei Security12b Title
Security12bTitle
Common stock, par value $0.0001 per share
CY2020 dei Trading Symbol
TradingSymbol
MIRM
CY2020 dei Security Exchange Name
SecurityExchangeName
NASDAQ
CY2019Q4 us-gaap Cash And Cash Equivalents At Carrying Value
CashAndCashEquivalentsAtCarryingValue
11970000
CY2019 us-gaap Investment Income Interest
InvestmentIncomeInterest
2232000
CY2020 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-192000
CY2019 us-gaap Other Nonoperating Income Expense
OtherNonoperatingIncomeExpense
-21000
CY2020 us-gaap Operating Income Loss
OperatingIncomeLoss
-104296000
CY2019 us-gaap Operating Income Loss
OperatingIncomeLoss
-54743000
CY2020 us-gaap Investment Income Interest
InvestmentIncomeInterest
1559000
CY2020 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
-46000
CY2019 us-gaap Profit Loss
ProfitLoss
-52553000
CY2019 us-gaap Share Based Compensation
ShareBasedCompensation
6070000
CY2020 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
74562000
CY2019 us-gaap Payments To Acquire Investments
PaymentsToAcquireInvestments
152000000
CY2020Q4 us-gaap Short Term Investments
ShortTermInvestments
89734000
CY2019Q4 us-gaap Short Term Investments
ShortTermInvestments
104690000
CY2020Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
4530000
CY2019Q4 us-gaap Prepaid Expense And Other Assets Current
PrepaidExpenseAndOtherAssetsCurrent
2703000
CY2020Q4 us-gaap Assets Current
AssetsCurrent
236350000
CY2019Q4 us-gaap Assets Current
AssetsCurrent
119363000
CY2020Q4 us-gaap Long Term Investments
LongTermInvestments
0
CY2019Q4 us-gaap Long Term Investments
LongTermInvestments
23292000
CY2020Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1293000
CY2019Q4 us-gaap Property Plant And Equipment Net
PropertyPlantAndEquipmentNet
1372000
CY2020Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
1949000
CY2019Q4 us-gaap Operating Lease Right Of Use Asset
OperatingLeaseRightOfUseAsset
2361000
CY2020Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
1272000
CY2019Q4 us-gaap Other Assets Noncurrent
OtherAssetsNoncurrent
324000
CY2020Q4 us-gaap Assets
Assets
240864000
CY2019Q4 us-gaap Assets
Assets
146712000
CY2020Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3151000
CY2019Q4 us-gaap Accounts Payable Current
AccountsPayableCurrent
3351000
CY2020Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
13411000
CY2019Q4 us-gaap Accrued Liabilities Current
AccruedLiabilitiesCurrent
9328000
CY2020Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
636000
CY2019Q4 us-gaap Operating Lease Liability Current
OperatingLeaseLiabilityCurrent
397000
CY2020Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
1264000
CY2019Q4 us-gaap Derivative Liabilities Current
DerivativeLiabilitiesCurrent
0
CY2020Q4 us-gaap Liabilities Current
LiabilitiesCurrent
18462000
CY2019Q4 us-gaap Liabilities Current
LiabilitiesCurrent
13076000
CY2020Q4 mirm Revenue Interest Liability Noncurrent
RevenueInterestLiabilityNoncurrent
47651000
CY2019Q4 mirm Revenue Interest Liability Noncurrent
RevenueInterestLiabilityNoncurrent
0
CY2020Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
2627000
CY2019Q4 us-gaap Operating Lease Liability Noncurrent
OperatingLeaseLiabilityNoncurrent
3251000
CY2020Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
29000
CY2019Q4 us-gaap Other Liabilities Noncurrent
OtherLiabilitiesNoncurrent
36000
CY2020Q4 us-gaap Liabilities
Liabilities
68769000
CY2019Q4 us-gaap Liabilities
Liabilities
16363000
CY2020Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2019Q4 us-gaap Commitments And Contingencies
CommitmentsAndContingencies
0
CY2020Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2019Q4 us-gaap Preferred Stock Value
PreferredStockValue
0
CY2020Q4 us-gaap Common Stock Value
CommonStockValue
3000
CY2019Q4 us-gaap Common Stock Value
CommonStockValue
2000
CY2020Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
345180000
CY2019Q4 us-gaap Additional Paid In Capital Common Stock
AdditionalPaidInCapitalCommonStock
200119000
CY2020Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-173171000
CY2019Q4 us-gaap Retained Earnings Accumulated Deficit
RetainedEarningsAccumulatedDeficit
-69901000
CY2020Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
83000
CY2019Q4 us-gaap Accumulated Other Comprehensive Income Loss Net Of Tax
AccumulatedOtherComprehensiveIncomeLossNetOfTax
129000
CY2020Q4 us-gaap Stockholders Equity
StockholdersEquity
172095000
CY2019Q4 us-gaap Stockholders Equity
StockholdersEquity
130349000
CY2020Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
240864000
CY2019Q4 us-gaap Liabilities And Stockholders Equity
LiabilitiesAndStockholdersEquity
146712000
CY2020Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
326000
CY2019 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-52424000
CY2019Q4 mirm Common Stock Shares Outstanding Subject To Repurchase
CommonStockSharesOutstandingSubjectToRepurchase
389649
CY2020 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
81605000
CY2019Q4 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2020Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2019Q4 us-gaap Preferred Stock Shares Issued
PreferredStockSharesIssued
0
CY2020Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2019Q4 us-gaap Preferred Stock Shares Outstanding
PreferredStockSharesOutstanding
0
CY2020Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
0
CY2019Q4 us-gaap Preferred Stock Liquidation Preference Value
PreferredStockLiquidationPreferenceValue
0
CY2020Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q4 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2020Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2019Q4 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
30032600
CY2019Q4 us-gaap Common Stock Shares Issued
CommonStockSharesIssued
22989987
CY2020Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
29776544
CY2019Q4 us-gaap Common Stock Shares Outstanding
CommonStockSharesOutstanding
22600338
CY2020Q4 mirm Common Stock Shares Outstanding Subject To Repurchase
CommonStockSharesOutstandingSubjectToRepurchase
256056
CY2019 us-gaap Research And Development Expense Excluding Acquired In Process Cost
ResearchAndDevelopmentExpenseExcludingAcquiredInProcessCost
42991000
CY2020 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
22691000
CY2019 us-gaap General And Administrative Expense
GeneralAndAdministrativeExpense
11752000
CY2020 us-gaap Operating Expenses
OperatingExpenses
104296000
CY2019 us-gaap Operating Expenses
OperatingExpenses
54743000
CY2020 mirm Other Nonoperating Interest Expense
OtherNonoperatingInterestExpense
335000
CY2019 mirm Other Nonoperating Interest Expense
OtherNonoperatingInterestExpense
0
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-103264000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest
IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest
-52532000
CY2020 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
6000
CY2019 us-gaap Income Tax Expense Benefit
IncomeTaxExpenseBenefit
21000
CY2020 us-gaap Net Income Loss
NetIncomeLoss
-103270000
CY2019 us-gaap Net Income Loss
NetIncomeLoss
-52553000
CY2020 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.09
CY2019 us-gaap Earnings Per Share Basic And Diluted
EarningsPerShareBasicAndDiluted
-4.58
CY2020 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
25251968
CY2019 us-gaap Weighted Average Number Of Share Outstanding Basic And Diluted
WeightedAverageNumberOfShareOutstandingBasicAndDiluted
11486367
CY2020 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
-75000
CY2019 us-gaap Other Comprehensive Income Availableforsale Securities Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeAvailableforsaleSecuritiesAdjustmentNetOfTaxPortionAttributableToParent
156000
CY2020 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
29000
CY2019 us-gaap Other Comprehensive Income Foreign Currency Transaction And Translation Adjustment Net Of Tax Portion Attributable To Parent
OtherComprehensiveIncomeForeignCurrencyTransactionAndTranslationAdjustmentNetOfTaxPortionAttributableToParent
-27000
CY2020 us-gaap Comprehensive Income Net Of Tax
ComprehensiveIncomeNetOfTax
-103316000
CY2018Q4 us-gaap Stockholders Equity
StockholdersEquity
-17313000
CY2019 us-gaap Stock Issued During Period Value New Issues
StockIssuedDuringPeriodValueNewIssues
67200000
CY2019 mirm Conversion Of Redeemable Convertible Preferred Stock To Common Stock Value
ConversionOfRedeemableConvertiblePreferredStockToCommonStockValue
119826000
CY2019 us-gaap Reclassifications Of Temporary To Permanent Equity
ReclassificationsOfTemporaryToPermanentEquity
6990000
CY2020 us-gaap Stock Issued During Period Value Stock Options Exercised
StockIssuedDuringPeriodValueStockOptionsExercised
328000
CY2020 us-gaap Stock Issued During Period Value Employee Stock Purchase Plan
StockIssuedDuringPeriodValueEmployeeStockPurchasePlan
456000
CY2020 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
12554000
CY2020 us-gaap Profit Loss
ProfitLoss
-103270000
CY2020 us-gaap Share Based Compensation
ShareBasedCompensation
12554000
CY2020 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
305000
CY2019 us-gaap Depreciation Depletion And Amortization
DepreciationDepletionAndAmortization
139000
CY2020 mirm Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
318000
CY2019 mirm Operating Lease Right Of Use Asset Amortization
OperatingLeaseRightOfUseAssetAmortization
185000
CY2020 mirm Non Cash Interest Expense Related To Revenue Interest Liability
NonCashInterestExpenseRelatedToRevenueInterestLiability
335000
CY2019 us-gaap Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value
AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue
6070000
CY2019 us-gaap Other Comprehensive Income Loss Before Tax Portion Attributable To Parent
OtherComprehensiveIncomeLossBeforeTaxPortionAttributableToParent
129000
CY2019 mirm Non Cash Interest Expense Related To Revenue Interest Liability
NonCashInterestExpenseRelatedToRevenueInterestLiability
0
CY2020 us-gaap Accretion Amortization Of Discounts And Premiums Investments
AccretionAmortizationOfDiscountsAndPremiumsInvestments
-72000
CY2019 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
3756461
CY2020 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
1827000
CY2019 us-gaap Increase Decrease In Prepaid Deferred Expense And Other Assets
IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets
2691000
CY2020 mirm Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
-94000
CY2019 mirm Increase Decrease In Operating Lease Right Of Use Asset
IncreaseDecreaseInOperatingLeaseRightOfUseAsset
33000
CY2020 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
954000
CY2019 us-gaap Increase Decrease In Other Operating Assets
IncreaseDecreaseInOtherOperatingAssets
160000
CY2020 mirm Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
3683000
CY2019 mirm Increase Decrease In Accounts Payable Accrued Expenses And Other Liabilities
IncreaseDecreaseInAccountsPayableAccruedExpensesAndOtherLiabilities
10058000
CY2020 mirm Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-385000
CY2019 mirm Increase Decrease In Operating Lease Liability
IncreaseDecreaseInOperatingLeaseLiability
-51000
CY2020 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-89075000
CY2019 us-gaap Net Cash Provided By Used In Operating Activities
NetCashProvidedByUsedInOperatingActivities
-39362000
CY2020 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
85900000
CY2019 us-gaap Proceeds From Maturities Prepayments And Calls Of Available For Sale Securities
ProceedsFromMaturitiesPrepaymentsAndCallsOfAvailableForSaleSecurities
24500000
CY2020 mirm Proceeds From Paydowns Of Investments
ProceedsFromPaydownsOfInvestments
26761000
CY2019 mirm Proceeds From Paydowns Of Investments
ProceedsFromPaydownsOfInvestments
0
CY2020 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
225000
CY2019 us-gaap Payments To Acquire Property Plant And Equipment
PaymentsToAcquirePropertyPlantAndEquipment
281000
CY2020 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
37874000
CY2019 us-gaap Net Cash Provided By Used In Investing Activities
NetCashProvidedByUsedInInvestingActivities
-127781000
CY2020 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
0
CY2019 us-gaap Proceeds From Issuance Of Preferred Stock And Preference Stock
ProceedsFromIssuanceOfPreferredStockAndPreferenceStock
59977000
CY2020 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
121087000
CY2019 us-gaap Proceeds From Issuance Initial Public Offering
ProceedsFromIssuanceInitialPublicOffering
67200000
CY2020 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
10000000
CY2019 us-gaap Proceeds From Issuance Of Private Placement
ProceedsFromIssuanceOfPrivatePlacement
0
CY2020 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
784000
CY2019 us-gaap Proceeds From Issuance Of Shares Under Incentive And Share Based Compensation Plans Including Stock Options
ProceedsFromIssuanceOfSharesUnderIncentiveAndShareBasedCompensationPlansIncludingStockOptions
0
CY2020 mirm Proceeds From Revenue Interest Liability
ProceedsFromRevenueInterestLiability
49575000
CY2019 mirm Proceeds From Revenue Interest Liability
ProceedsFromRevenueInterestLiability
0
CY2020 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
158000
CY2019 us-gaap Payment Of Financing And Stock Issuance Costs
PaymentOfFinancingAndStockIssuanceCosts
0
CY2020 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
181288000
CY2019 us-gaap Net Cash Provided By Used In Financing Activities
NetCashProvidedByUsedInFinancingActivities
127177000
CY2020 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
29000
CY2019 us-gaap Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
-27000
CY2020 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
130116000
CY2019 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect
-39993000
CY2019Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
11970000
CY2018Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
51963000
CY2020Q4 us-gaap Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations
CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsIncludingDisposalGroupAndDiscontinuedOperations
142086000
CY2020 us-gaap Income Taxes Paid
IncomeTaxesPaid
11000
CY2019 us-gaap Income Taxes Paid
IncomeTaxesPaid
21000
CY2020 us-gaap Operating Lease Payments
OperatingLeasePayments
576000
CY2019 us-gaap Operating Lease Payments
OperatingLeasePayments
170000
CY2020 mirm Revenue Interest Liability Issuance Costs Included In Accrued Liabilities
RevenueInterestLiabilityIssuanceCostsIncludedInAccruedLiabilities
229000
CY2019 mirm Revenue Interest Liability Issuance Costs Included In Accrued Liabilities
RevenueInterestLiabilityIssuanceCostsIncludedInAccruedLiabilities
0
CY2020 mirm Deferred Offering Costs Included In Accrued Liabilities
DeferredOfferingCostsIncludedInAccruedLiabilities
129000
CY2019 mirm Deferred Offering Costs Included In Accrued Liabilities
DeferredOfferingCostsIncludedInAccruedLiabilities
164000
CY2020 mirm Compound Derivative Liability Related To Revenue Interest Liability
CompoundDerivativeLiabilityRelatedToRevenueInterestLiability
1264000
CY2019 mirm Compound Derivative Liability Related To Revenue Interest Liability
CompoundDerivativeLiabilityRelatedToRevenueInterestLiability
0
CY2020 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
0
CY2019 us-gaap Right Of Use Asset Obtained In Exchange For Operating Lease Liability
RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability
3700000
CY2020 us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
0
CY2019 us-gaap Payments For Tenant Improvements
PaymentsForTenantImprovements
1231000
CY2020 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
0
CY2019 us-gaap Conversion Of Stock Amount Issued1
ConversionOfStockAmountIssued1
119826000
CY2020 mirm Reclassification Of Redeemable Common Stock Into Common Stock
ReclassificationOfRedeemableCommonStockIntoCommonStock
0
CY2019 mirm Reclassification Of Redeemable Common Stock Into Common Stock
ReclassificationOfRedeemableCommonStockIntoCommonStock
6990000
CY2020 us-gaap Use Of Estimates
UseOfEstimates
<p style="margin-bottom:0pt;margin-top:10pt;margin-left:4.94%;text-indent:0%;font-weight:bold;font-style:italic;font-size:10pt;font-family:Times New Roman;text-transform:none;font-variant: normal;">Use of Estimates </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The preparation of consolidated financial statements in accordance with GAAP requires management to make estimates and assumptions that impact the reported amounts of assets, liabilities and expenses and the disclosure of contingent assets and liabilities in the financial statements and accompanying notes. The most significant estimates in the Company&#8217;s consolidated financial statements relate to the revenue interest liability, accrued research and development expenses, the valuation of derivative liabilities and the valuation allowance of deferred tax assets resulting from net operating losses. These estimates and assumptions are based upon historical experience, knowledge of current events and various other factors believed to be reasonable under the circumstances, the results of which form the basis for making judgments about the carrying values of assets and liabilities and the recording of expenses that are not readily apparent from other sources. Actual results could differ materially from those estimates. </p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In December 2019, a novel strain of coronavirus, which causes COVID-19, was identified. Due to the rapid and global spread of the virus, on March 11, 2020, the World Health Organization declared the COVID-19 outbreak a pandemic. To slow the proliferation of COVID-19, governments have implemented extraordinary measures, which include the mandatory closure of businesses, restrictions on travel and gatherings, and quarantine and physical distancing requirements.</p> <p style="margin-bottom:0pt;margin-top:10pt;text-indent:4.94%;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">There were no significant estimates contained in the preparation of the Company&#8217;s consolidated financial statements or impacts to the Company&#8217;s consolidated financial statements for the year ended December 31, 2020 that were directly a result of the COVID-19 pandemic. The Company is not aware of any specific event or circumstance that would require an update to its estimates, judgments and assumptions or a revision of the carrying value of the Company&#8217;s assets or liabilities as of the date of this filing.</p>
CY2019Q3 us-gaap Stockholders Equity Note Stock Split Conversion Ratio1
StockholdersEquityNoteStockSplitConversionRatio1
0.125
CY2019Q3 us-gaap Stockholders Equity Reverse Stock Split
StockholdersEquityReverseStockSplit
In July 2019, the Company effected a 1-for-8 reverse stock split of its common stock. The par value and the authorized number of shares of common stock were not adjusted as a result of the reverse stock split. The reverse stock split resulted in an adjustment to the conversion price of the Company’s Series A redeemable convertible preferred stock (the “Series A Preferred Stock”) to reflect a proportional decrease in the number of shares of common stock to be issued upon conversion.
CY2020Q4 mirm Cash Cash Equivalents And Short And Long Term Investments
CashCashEquivalentsAndShortAndLongTermInvestments
231800000
CY2020 mirm Investments Classified As Cash And Cash Equivalent Original Maturities
InvestmentsClassifiedAsCashAndCashEquivalentOriginalMaturities
P3M
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Noncurrent
AvailableForSaleSecuritiesDebtSecuritiesNoncurrent
23292000
CY2020 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2019 us-gaap Available For Sale Securities Gross Realized Gain Loss Net
AvailableForSaleSecuritiesGrossRealizedGainLossNet
0
CY2020Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2019Q4 us-gaap Debt Securities Available For Sale Continuous Unrealized Loss Position12 Months Or Longer
DebtSecuritiesAvailableForSaleContinuousUnrealizedLossPosition12MonthsOrLonger
0
CY2019 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2020Q4 mirm Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
3673000
CY2019Q4 mirm Accrued Clinical Trials Current
AccruedClinicalTrialsCurrent
4795000
CY2020Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
2157000
CY2019Q4 us-gaap Accrued Professional Fees Current
AccruedProfessionalFeesCurrent
777000
CY2020Q4 mirm Accrued Contract Manufacturing And Non Clinical Costs Current
AccruedContractManufacturingAndNonClinicalCostsCurrent
2780000
CY2019Q4 mirm Accrued Contract Manufacturing And Non Clinical Costs Current
AccruedContractManufacturingAndNonClinicalCostsCurrent
1540000
CY2020Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
4801000
CY2019Q4 us-gaap Employee Related Liabilities Current
EmployeeRelatedLiabilitiesCurrent
2216000
CY2020 dei Entity Incorporation Date Of Incorporation
EntityIncorporationDateOfIncorporation
2018-05-02
CY2020 us-gaap Number Of Operating Segments
NumberOfOperatingSegments
1
CY2020Q4 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
229513000
CY2020Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
139779000
CY2020Q4 mirm Revenue Interest Liability
RevenueInterestLiability
49234000
CY2020Q4 mirm Interest Expense Accrued
InterestExpenseAccrued
335000
CY2020Q4 mirm Debt Issuances Costs Capitalized
DebtIssuancesCostsCapitalized
-654000
CY2020Q4 mirm Debt Discount From Embedded Derivatives
DebtDiscountFromEmbeddedDerivatives
-1264000
CY2020Q4 mirm Revenue Interest Liability
RevenueInterestLiability
47651000
CY2019Q1 us-gaap Area Of Land
AreaOfLand
5600
CY2019Q1 us-gaap Lessee Operating Lease Term Of Contract
LesseeOperatingLeaseTermOfContract
P4Y
CY2020 us-gaap Lessee Operating Lease Option To Extend
LesseeOperatingLeaseOptionToExtend
The lease term is approximately four years with an option to extend the term for one five-year term, which at the time was not reasonably assured of exercise and therefore, not included in the lease term.
CY2020Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
89734000
CY2019Q4 mirm Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
138447000
CY2019Q4 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
157000
CY2019Q4 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2019Q4 mirm Cash Equivalents And Available For Sale Securities Debt Securities
CashEquivalentsAndAvailableForSaleSecuritiesDebtSecurities
138603000
CY2019Q4 us-gaap Cash And Cash Equivalents Fair Value Disclosure
CashAndCashEquivalentsFairValueDisclosure
10621000
CY2019Q4 us-gaap Available For Sale Securities Debt Securities Current
AvailableForSaleSecuritiesDebtSecuritiesCurrent
104690000
CY2020 us-gaap Other Than Temporary Impairment Loss Debt Securities Available For Sale
OtherThanTemporaryImpairmentLossDebtSecuritiesAvailableForSale
0
CY2020Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
300000
CY2019Q4 us-gaap Accumulated Depreciation Depletion And Amortization Property Plant And Equipment
AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment
100000
CY2020 us-gaap Impairment Of Long Lived Assets To Be Disposed Of
ImpairmentOfLongLivedAssetsToBeDisposedOf
0
CY2020 mirm Life Of Shelf Registration
LifeOfShelfRegistration
P3Y
CY2020Q4 mirm Deferred Offering Costs Under Shelf Registration
DeferredOfferingCostsUnderShelfRegistration
59000000
CY2020 us-gaap Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount
AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount
5903227
CY2020Q4 mirm Cash Equivalents And Available For Sale Debt Securities Amortized Cost Basis
CashEquivalentsAndAvailableForSaleDebtSecuritiesAmortizedCostBasis
229432000
CY2020Q4 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Gain Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax
82000
CY2020Q4 mirm Cash Equivalents And Available For Sale Debt Securities Accumulated Gross Unrealized Loss Before Tax
CashEquivalentsAndAvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax
1000
CY2020 us-gaap Lessee Operating Lease Existence Of Option To Extend
LesseeOperatingLeaseExistenceOfOptionToExtend
true
CY2019Q1 us-gaap Lessee Operating Lease Renewal Term
LesseeOperatingLeaseRenewalTerm
P5Y
CY2019Q1 mirm Tenant Improvement Allowance
TenantImprovementAllowance
400000
CY2020Q4 us-gaap Operating Lease Liability
OperatingLeaseLiability
3263000
CY2020Q4 us-gaap Operating Lease Weighted Average Remaining Lease Term1
OperatingLeaseWeightedAverageRemainingLeaseTerm1
P4Y1M6D
CY2020Q4 us-gaap Operating Lease Weighted Average Discount Rate Percent
OperatingLeaseWeightedAverageDiscountRatePercent
0.080
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Next Twelve Months
LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths
869000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Two
LesseeOperatingLeaseLiabilityPaymentsDueYearTwo
893000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Three
LesseeOperatingLeaseLiabilityPaymentsDueYearThree
922000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Four
LesseeOperatingLeaseLiabilityPaymentsDueYearFour
930000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due Year Five
LesseeOperatingLeaseLiabilityPaymentsDueYearFive
230000
CY2020Q4 us-gaap Lessee Operating Lease Liability Payments Due
LesseeOperatingLeaseLiabilityPaymentsDue
3844000
CY2020 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
27800000
CY2019 us-gaap Valuation Allowance Deferred Tax Asset Change In Amount
ValuationAllowanceDeferredTaxAssetChangeInAmount
13600000
CY2020Q4 us-gaap Lessee Operating Lease Liability Undiscounted Excess Amount
LesseeOperatingLeaseLiabilityUndiscountedExcessAmount
581000
CY2020 us-gaap Operating Lease Expense
OperatingLeaseExpense
600000
CY2019 us-gaap Operating Lease Expense
OperatingLeaseExpense
300000
CY2019Q3 us-gaap Preferred Stock Par Or Stated Value Per Share
PreferredStockParOrStatedValuePerShare
0.0001
CY2019Q3 us-gaap Preferred Stock Shares Authorized
PreferredStockSharesAuthorized
10000000
CY2019Q3 us-gaap Common Stock Par Or Stated Value Per Share
CommonStockParOrStatedValuePerShare
0.0001
CY2019Q3 us-gaap Common Stock Shares Authorized
CommonStockSharesAuthorized
200000000
CY2020Q3 mirm Maximum Amount Of Sale Covered In Shelf Registration Statement
MaximumAmountOfSaleCoveredInShelfRegistrationStatement
300000000
CY2020Q4 mirm Common Stock Aggregate Offering Price Remaining
CommonStockAggregateOfferingPriceRemaining
68400000
CY2020Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
8343673
CY2019Q4 us-gaap Common Stock Capital Shares Reserved For Future Issuance
CommonStockCapitalSharesReservedForFutureIssuance
4979255
CY2020 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
12554000
CY2019 us-gaap Allocated Share Based Compensation Expense
AllocatedShareBasedCompensationExpense
6070000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-103371000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Domestic
IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic
-52654000
CY2020 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
107000
CY2019 us-gaap Income Loss From Continuing Operations Before Income Taxes Foreign
IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign
122000
CY2020 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
6000
CY2019 us-gaap Current Foreign Tax Expense Benefit
CurrentForeignTaxExpenseBenefit
21000
CY2020 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2019 us-gaap Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate
EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate
0.2100
CY2020 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
0.0042
CY2019 us-gaap Effective Income Tax Rate Reconciliation State And Local Income Taxes
EffectiveIncomeTaxRateReconciliationStateAndLocalIncomeTaxes
-0.0162
CY2020 mirm Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.0089
CY2019 mirm Effective Income Tax Rate Reconciliation Permanent Differences
EffectiveIncomeTaxRateReconciliationPermanentDifferences
0.0078
CY2020 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0642
CY2019 us-gaap Effective Income Tax Rate Reconciliation Tax Credits
EffectiveIncomeTaxRateReconciliationTaxCredits
0.0732
CY2020 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2696
CY2019 us-gaap Effective Income Tax Rate Reconciliation Change In Deferred Tax Assets Valuation Allowance
EffectiveIncomeTaxRateReconciliationChangeInDeferredTaxAssetsValuationAllowance
-0.2595
CY2020 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0001
CY2019 us-gaap Effective Income Tax Rate Continuing Operations
EffectiveIncomeTaxRateContinuingOperations
-0.0003
CY2020Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
26122000
CY2019Q4 us-gaap Deferred Tax Assets Operating Loss Carryforwards
DeferredTaxAssetsOperatingLossCarryforwards
9486000
CY2020Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
11294000
CY2019Q4 us-gaap Deferred Tax Assets Tax Credit Carryforwards
DeferredTaxAssetsTaxCreditCarryforwards
4378000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
812000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Reserves And Accruals
DeferredTaxAssetsTaxDeferredExpenseReservesAndAccruals
364000
CY2020Q4 mirm Deferred Tax Assets Intangible Assets
DeferredTaxAssetsIntangibleAssets
5560000
CY2019Q4 mirm Deferred Tax Assets Intangible Assets
DeferredTaxAssetsIntangibleAssets
3570000
CY2020Q4 mirm Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
661000
CY2019Q4 mirm Deferred Tax Assets Lease Liability
DeferredTaxAssetsLeaseLiability
737000
CY2020Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
2769000
CY2019Q4 us-gaap Deferred Tax Assets Tax Deferred Expense Compensation And Benefits Share Based Compensation Cost
DeferredTaxAssetsTaxDeferredExpenseCompensationAndBenefitsShareBasedCompensationCost
989000
CY2020Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
47218000
CY2019Q4 us-gaap Deferred Tax Assets Gross
DeferredTaxAssetsGross
19524000
CY2020Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
385000
CY2019Q4 us-gaap Deferred Tax Liabilities Leasing Arrangements
DeferredTaxLiabilitiesLeasingArrangements
468000
CY2020Q4 mirm Deferred Tax Liabilities Fixed Assets
DeferredTaxLiabilitiesFixedAssets
184000
CY2019Q4 mirm Deferred Tax Liabilities Fixed Assets
DeferredTaxLiabilitiesFixedAssets
228000
CY2020Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
569000
CY2019Q4 us-gaap Deferred Income Tax Liabilities
DeferredIncomeTaxLiabilities
696000
CY2020Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
46649000
CY2019Q4 us-gaap Deferred Tax Assets Valuation Allowance
DeferredTaxAssetsValuationAllowance
18828000
CY2020Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2019Q4 us-gaap Deferred Tax Assets Liabilities Net
DeferredTaxAssetsLiabilitiesNet
0
CY2019Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
1490000
CY2018Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
116000
CY2020 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
17000
CY2019 us-gaap Unrecognized Tax Benefits Decreases Resulting From Prior Period Tax Positions
UnrecognizedTaxBenefitsDecreasesResultingFromPriorPeriodTaxPositions
20000
CY2020 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
2460000
CY2019 us-gaap Unrecognized Tax Benefits Increases Resulting From Current Period Tax Positions
UnrecognizedTaxBenefitsIncreasesResultingFromCurrentPeriodTaxPositions
1394000
CY2020Q4 us-gaap Unrecognized Tax Benefits
UnrecognizedTaxBenefits
3933000
CY2020Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
3600000
CY2019Q4 us-gaap Unrecognized Tax Benefits That Would Impact Effective Tax Rate
UnrecognizedTaxBenefitsThatWouldImpactEffectiveTaxRate
1500000
CY2020Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2019Q4 us-gaap Unrecognized Tax Benefits Income Tax Penalties And Interest Accrued
UnrecognizedTaxBenefitsIncomeTaxPenaltiesAndInterestAccrued
0
CY2020Q4 us-gaap Undistributed Earnings Of Foreign Subsidiaries
UndistributedEarningsOfForeignSubsidiaries
0
CY2019Q4 us-gaap Undistributed Earnings Of Foreign Subsidiaries
UndistributedEarningsOfForeignSubsidiaries
0

Files In Submission

Name View Source Status
0001564590-21-011756-index-headers.html Edgar Link pending
0001564590-21-011756-index.html Edgar Link pending
0001564590-21-011756.txt Edgar Link pending
0001564590-21-011756-xbrl.zip Edgar Link pending
FilingSummary.xml Edgar Link unprocessable
Financial_Report.xlsx Edgar Link pending
gjjkn51jbi5n000001.jpg Edgar Link pending
gjjkn51jbi5n000002.jpg Edgar Link pending
gjjkn51jbi5n000003.jpg Edgar Link pending
gjjkn51jbi5n000004.jpg Edgar Link pending
gjjkn51jbi5n000005.jpg Edgar Link pending
gjjkn51jbi5n000006.jpg Edgar Link pending
gjjkn51jbi5n000007.jpg Edgar Link pending
gjjkn51jbi5n000008.jpg Edgar Link pending
gjjkn51jbi5n000009.jpg Edgar Link pending
gjjkn51jbi5n000010.jpg Edgar Link pending
gjjkn51jbi5n000011.jpg Edgar Link pending
gjjkn51jbi5n000012.jpg Edgar Link pending
gjjkn51jbi5n000013.jpg Edgar Link pending
gjjkn51jbi5n000014.jpg Edgar Link pending
gjjkn51jbi5n000015.jpg Edgar Link pending
gjjkn51jbi5n000016.jpg Edgar Link pending
gjjkn51jbi5n000017.jpg Edgar Link pending
gjjkn51jbi5n000018.jpg Edgar Link pending
gjjkn51jbi5n000019.jpg Edgar Link pending
gjjkn51jbi5n000020.jpg Edgar Link pending
gjjkn51jbi5n000021.jpg Edgar Link pending
gjjkn51jbi5n000022.jpg Edgar Link pending
mirm-10k_20201231.htm Edgar Link pending
mirm-20201231.xml Edgar Link completed
mirm-20201231.xsd Edgar Link pending
mirm-20201231_cal.xml Edgar Link unprocessable
mirm-20201231_def.xml Edgar Link unprocessable
mirm-20201231_lab.xml Edgar Link unprocessable
mirm-20201231_pre.xml Edgar Link unprocessable
mirm-ex1018_182.htm Edgar Link pending
mirm-ex231_7.htm Edgar Link pending
mirm-ex311_8.htm Edgar Link pending
mirm-ex312_9.htm Edgar Link pending
mirm-ex321_10.htm Edgar Link pending
mirm-ex322_11.htm Edgar Link pending
R1.htm Edgar Link pending
R10.htm Edgar Link pending
R11.htm Edgar Link pending
R12.htm Edgar Link pending
R13.htm Edgar Link pending
R14.htm Edgar Link pending
R15.htm Edgar Link pending
R16.htm Edgar Link pending
R17.htm Edgar Link pending
R18.htm Edgar Link pending
R19.htm Edgar Link pending
R2.htm Edgar Link pending
R20.htm Edgar Link pending
R21.htm Edgar Link pending
R22.htm Edgar Link pending
R23.htm Edgar Link pending
R24.htm Edgar Link pending
R25.htm Edgar Link pending
R26.htm Edgar Link pending
R27.htm Edgar Link pending
R28.htm Edgar Link pending
R29.htm Edgar Link pending
R3.htm Edgar Link pending
R30.htm Edgar Link pending
R31.htm Edgar Link pending
R32.htm Edgar Link pending
R33.htm Edgar Link pending
R34.htm Edgar Link pending
R35.htm Edgar Link pending
R36.htm Edgar Link pending
R37.htm Edgar Link pending
R38.htm Edgar Link pending
R39.htm Edgar Link pending
R4.htm Edgar Link pending
R40.htm Edgar Link pending
R41.htm Edgar Link pending
R42.htm Edgar Link pending
R43.htm Edgar Link pending
R44.htm Edgar Link pending
R45.htm Edgar Link pending
R46.htm Edgar Link pending
R47.htm Edgar Link pending
R48.htm Edgar Link pending
R49.htm Edgar Link pending
R5.htm Edgar Link pending
R50.htm Edgar Link pending
R51.htm Edgar Link pending
R52.htm Edgar Link pending
R53.htm Edgar Link pending
R54.htm Edgar Link pending
R55.htm Edgar Link pending
R6.htm Edgar Link pending
R7.htm Edgar Link pending
R8.htm Edgar Link pending
R9.htm Edgar Link pending
report.css Edgar Link pending
Show.js Edgar Link pending